

TEST CHANGE

Lacosamide, Serum or Plasma

2003182, LACOSA SP

Specimen Requirements:

Patient Preparation: Timing of specimen collection: Pre-dose (trough) draw - At

steady state concentration.

Collect: Plain red. Also acceptable: Lavender (K2 or K3EDTA) or pink

(K2EDTA).

Specimen Preparation: Separate serum or plasma from cells within 2 hours of

collection. Transfer 1 mL serum or plasma to an ARUP

Effective Date: August 21, 2023

Standard Transport Tube. (Min: 0.5 mL)

Transport Temperature: Refrigerated: Also acceptable: Room temperature or frozen.

Unacceptable Conditions: Whole blood. Gel separator tubes, light blue (citrate), or yellow

(SPS or ACD solution).

Remarks:

Stability: Ambient: <u>72 hours 15 days</u>; Refrigerated: <u>2 weeks 15 days</u>;

Frozen: 2 weeks 15 days

Methodology: Quantitative High Performance Liquid Chromatography-Tandem

Mass Spectrometry

Performed: <u>Mon-FriSun-Sat</u>

Reported: 1-4 days

Note:

CPT Codes: 80235

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Lacosamide is an anticonvulsant drug indicated for adjunctive therapy for partial-onset seizures. The therapeutic range is based on serum, predose (trough) draw collection at steady-state concentration. Adverse effects may include dizziness, fatigue, nausea, vomiting, blurred vision, and tremor.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Reference Interval:



Effective November 15, 2021

Effective Date: August 21, 2023